Kymera Therapeutics

Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis

Study to Evaluate IRAK4 Levels in Skin and Blood and Relationship to Inflammatory Biomarkers and Disease Stage Cambridge, Mass. (June 3, 2020) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients,